查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024648

單株抗體市場報告：按生產方法、原料、適應症、最終用途和地區分類（2026-2034 年）

Monoclonal Antibodies Market Report by Production Method, Source, Indication, End Use, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

2025年全球單株抗體市場規模達2,501億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以5.80%的複合年成長率成長，到2034年達到4,218億美元。北美地區憑藉其先進的醫療保健體系、大量的醫藥投資、對各種疾病創新治療方法的高需求以及眾多大型製藥公司的存在，成為推動市場成長的主要力量。癌症、自體免疫疾病和感染疾病等慢性疾病的日益普遍、雙特異性抗體和抗體藥物複合體（ADC）等創新療法的出現、人口老齡化以及腫瘤學和免疫療法的拓展，都對市場成長起到了促進作用。

市場規模及預測：

  • 2025年單株抗體市值將達2,501億美元。
  • 預計從 2026 年到 2034 年，該產業將以 5.80% 的複合年成長率成長，到 2034 年達到 4,218 億美元。

主要部分：

  • 產品：體外（體外檢測）檢測憑藉其準確性、可靠性以及快速精準的篩檢能力，佔據了最大的市場佔有率。此方法提高了抗體生產效率，實現了更精準的治療，並顯著降低了臨床應用所需的時間和成本。
  • 資料來源：人源抗體佔市場主導。這是因為單株抗體與人體免疫系統具有更高的相容性，從而降低了免疫反應的風險並提高了治療效果。單株抗體能夠極為精準地針對特定抗原，不僅增強了治療效果，也確保了患者安全。
  • 適應症：隨著全球癌症發生率的上升和對標靶治療需求的不斷成長，腫瘤治療領域展現出壓倒性的市場主導地位。單株抗體具有精準性高、存活率高、副作用小等優點，是一種極具前景的治療選擇，在癌症治療中備受青睞。
  • 最終用戶：醫院佔最大市場佔有率，因為它們擁有尖端醫療技術、合格的醫護人員以及提供專業治療的能力。醫院在單株抗體療法的實施中發揮著至關重要的作用，確保有效的患者管理、治療的安全性和有效性。
  • 區域：北美憑藉其先進的醫療設施、大量的研發投入和嚴格的監管要求，正引領單株抗體市場的發展。此外，該地區對尖端治療方法的需求旺盛，也加速了單株抗體的快速普及和應用。

主要公司：

  • 單株抗體市場的主要參與者包括艾伯維公司、安進公司、百時美施貴寶公司、禮來公司、羅氏公司、葛蘭素史克公司、強生公司、默克集團、諾華製藥公司、輝瑞公司、賽諾菲公司和武田藥品工業株式會社。

市場成長的主要促進因素：

  • 個人化醫療日益普及：個人化醫療的日益普及正對單株抗體市場產生積極影響，因為它能夠根據每位患者的特定特徵量身定做治療方案。這種策略可以更精準地靶向疾病相關分子，尤其是在癌症和遺傳性疾病等領域，從而最大限度地減少副作用並提高治療效果。
  • 單株抗體研發領域的投資：對單株抗體研發的大量投資正在加速該領域的發展。創業投資和私募股權公司的投資正在推動研究、臨床試驗和生產，從而促進新療法的快速開發和應用。
  • 生物相似藥需求不斷成長：隨著醫療系統致力於降低醫療成本，對生物相似藥的需求日益成長，從而提高了單株抗體療法的可及性。新生物相似藥的上市拓寬了治療選擇，同時也加劇了市場競爭。
  • 支持性的法規環境：監管機構正在加強生物製藥的核准程序，提供靈活的臨床試驗框架，並加速高需求治療方法的核准。這種監管支持鼓勵製藥公司投資於單株抗體的研發。
  • 慢性病盛行率上升：癌症和自體免疫疾病等慢性病發病率的不斷上升，推動了對單株抗體的需求。這些疾病需要持續治療，而單株抗體因其治療方法精準高效且副作用較小，成為患者和醫護人員的首選。
  • 生物製造技術的進步：細胞株開發、蛋白質表現系統和生物反應器設計的改進提高了單株抗體生產的擴充性和效率。這些進步降低了生產成本，提高了產量，並確保了品質的穩定性，使單株抗體療法更具成本效益，並能應用於更廣泛的疾病治療。

未來展望：

  • 強勁成長前景：受標靶治療需求成長、生物技術進步以及單株抗體在各個治療領域應用範圍不斷擴大的推動，單株抗體市場呈現成長態勢。持續的研發投入以及醫療保健領域投資的增加，進一步促進了市場的持續擴張和創新潛力。
  • 市場演變：單株抗體市場正經歷顯著的變革，這主要得益於技術進步和對個人化醫療日益成長的關注。持續的研發投入正在提高治療的精準性和有效性，創造新的應用，並擴大其在各個治療領域的市場潛力。

單株抗體（mAbs）是實驗室生產的蛋白質，其功能類似抗體，能夠增強、修飾、恢復或模擬免疫系統對有害細胞的攻擊。它們透過激活免疫系統來檢測和靶向癌細胞。此外，它們也用於抑制癌細胞與促進細胞增殖的蛋白質的結合。而且，它們還能抑制某些蛋白質的形成，這些蛋白質對於免疫系統有效對抗癌細胞至關重要。另外，單株抗體還能將放射療法直接輸送到癌細胞，進而最大限度地減少輻射對健康細胞的影響。

單株抗體市場趨勢：

人們對個人化醫療的興趣日益濃厚

個人化醫療的興起是推動市場發展的關鍵因素，它能夠根據每位患者的個別情況制定更精準、更有效的治療方案。這種方法基於遺傳、環境和生活方式等因素為每位患者量身定做醫療方案，使得單株抗體成為治療特定疾病的首選。這些治療方法能夠精準標靶化致病細胞和分子，這對於癌症和遺傳性疾病等病症至關重要。個人化醫療因其能夠提高治療效率並減少副作用，正吸引著患者和醫療專業人員的廣泛關注。隨著醫療系統向標靶治療轉型，對單株抗體的需求日益成長。這項轉變推動了研發工作，促使人們開發出針對各種基因譜和疾病指標的單株抗體療法，確保滿足每位患者的個別需求。

對單株抗體研發的投資

對單株抗體研發投入的增加是市場成長的關鍵驅動力，加速了針對多種疾病的標靶治療的發現、生產和商業化。創業投資和私募股權公司認知到單株抗體在治療包括發炎性疾病、自體免疫疾病和癌症相關疾病在內的多種疾病方面的潛力，從而為生物技術公司帶來了大量資金流入。這些投資支持研發和臨床試驗，加速了新型單株抗體療法的發現。資金流入促進了創新，使公司能夠推進其單株抗體產品線，並將創新治療方法推向市場。 2024年，Calluna Pharma在A輪資金籌措中籌集了8,100萬美元，用於推進其針對發炎和纖維化疾病的單株抗體產品線。該公司由Oxitope Pharma和Arxx Therapeutics合併而成，正在開發四種單株抗體，包括CAL101，用於治療類風濕性關節炎和特發性肺纖維化等疾病。這筆資金將用於支持他們的後續研發和臨床試驗。

生物相似藥需求不斷成長

與已已通過核准的參考單株抗體高度相似的生物相似藥，在維持療效的同時，提供了更經濟實惠的選擇。隨著全球醫療保健系統面臨應對不斷上漲的治療成本的壓力，生物相似藥物透過提高單株抗體療法的可及性和可負擔性，提供了一個切實可行的解決方案。這對於癌症等需要長期治療且可能造成沉重經濟負擔的慢性疾病的管理尤其重要。更多生物相似藥的核准和上市，拓寬了患者的治療選擇，加劇了市場競爭，並促進了整個產業的成長。順應這一趨勢，瑞迪博士實驗室於領先年在英國市場推出了其首個生物相似藥Versavo（Bevacizumab）。 Versavo是Avastin的單株抗體生物相似藥，已被用於治療多種癌症，包括大腸直腸癌和乳癌。此前，Versavo已在印度、泰國和烏克蘭等市場上市。

單株抗體市場成長要素：

支持性的法規環境

單株抗體市場受益於不斷改善且有利的法規環境。監管機構正在簡化包括單株抗體在內的生物製藥的核准流程，以加快患者獲得關鍵治療方法的速度。針對高需求治療方法的法規結構日益完善，核准途徑也更加快捷，這使得企業能夠更快地將新的單株抗體療法推向市場。此外，監管機構正在提高臨床試驗設計的柔軟性，從而更容易在不同病患小組中評估這些治療方法。這種監管支持鼓勵製藥公司投資於單株抗體的研發，因為他們可以期待更一致、更有效率的核准流程。隨著各國政府意識到創新治療方法的重要性，監管環境仍是推動市場成長的關鍵因素。近期發布的單株抗體市場報告表明，這種監管支持將進一步加速產業擴張。

慢性病盛行率增加

癌症、自體免疫疾病和心臟病等慢性疾病的日益普遍是單株抗體市場成長的主要驅動力。這些疾病需要持續治療，而單株抗體因其能夠精準高效地靶向致病分子而特別有效。人口老化也加劇了這一趨勢，因為老年人更容易患上這些疾病。此外，聯合國人口預測顯示，2024年至2074年間，這一比例將翻倍，達到20.7%。在對標靶治療需求不斷成長的背景下，單株抗體為患者和醫療保健系統提供了極具價值的解決方案。與傳統治療方法相比，這些治療方法能夠提供更精準、更有效的治療效果，且副作用更少。因此，製藥公司正大力投資研發針對多種疾病的單株抗體，進一步推動市場成長。

生物製造技術的進步

細胞株建構、蛋白質表現技術和生物反應器設計的最新進展提高了單株抗體生產的效率和規模化能力。這些技術進步有助於降低生產成本、提高產量和保證產品品質的穩定性，從而使單株抗體療法更具成本效益和可及性。此外，製程最佳化和自動化技術的進步提高了生產過程控制的精確度，並提升了整體生產效率。隨著這些技術的不斷發展，大規模生產的可行性日益提高，加速了單株抗體在更廣泛治療領域的應用。 2024年，藥明生物推出了「藥明瑞德GS」平台，這是一個用於非抗生素細胞株開發的高產量GS基因敲除CHO細胞株系統。該平台可實現高達6 g/L的表達水平，確保單株抗體（mAb）和其他治療藥物的穩定性，並支持產品品質的穩定性和細胞株的長期穩定性。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球單株抗體市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依生產方式分類

  • 體內
  • 體外

第7章 市場區隔：依來源

  • 老鼠
  • 嵌合體
  • 人性化
  • 人類

第8章 市場區隔：依適應症分類

  • 癌症
  • 自體免疫疾病
  • 發炎性疾病
  • 感染疾病
  • 其他

第9章 市場區隔：依最終用途分類

  • 醫院
  • 研究機構
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • AbbVie Inc.
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GSK plc
    • Johnson & Johnson
    • Merck KGaA
    • Novartis Pharmaceuticals Corporation
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
Product Code: SR112026A6278

The global monoclonal antibodies market size reached USD 250.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 421.8 Billion by 2034, exhibiting a growth rate (CAGR) of 5.80% during 2026-2034. North America leads the market because of its sophisticated medical framework, considerable pharmaceutical investments, a high demand for innovative treatments for various diseases, and the presence of key pharmaceutical companies. The rising prevalence of chronic disorders such as cancer, autoimmune disorders, and infectious diseases, innovations like bispecific antibodies and antibody-drug conjugates (ADCs), increasing geriatric population, and the expansion in oncology and immunotherapy are propelling the market growth.

MARKET SIZE & FORECASTS:

  • Monoclonal antibodies market was valued at USD 250.1 Billion in 2025.
  • The market is projected to reach USD 421.8 Billion by 2034, at a CAGR of 5.80% from 2026-2034.

DOMINANT SEGMENTS:

  • Product : In vitro hold the biggest market share because of its accuracy, dependability, and capacity for swift and precise screening. This approach improves the effectiveness of antibody creation, facilitates more precise therapies, and markedly decreases the time and expenses linked to clinical uses.
  • Source : Human leads the market attributed to the enhanced compatibility of monoclonal antibodies with the human immune system, which lowers the chances of immune responses and improves therapeutic effectiveness. The capacity of monoclonal antibodies to pinpoint particular antigens with great accuracy enhances treatment results and ensures patient safety.
  • Indication: Cancer exhibits a clear dominance in the market owing to the rising incidence of cancer globally and the increasing need for targeted treatments. Monoclonal antibodies present hopeful treatment choices, delivering accuracy, enhanced survival rates, and limited side effects, rendering them highly desirable in cancer care.
  • End Use: Hospitals represent the largest segment accredited to their access to cutting-edge medical technologies, qualified healthcare providers, and capacity to deliver specialized treatment. Hospitals play a crucial role in delivering monoclonal antibody therapies, guaranteeing effective patient oversight, safety, and effectiveness in treatment implementation.
  • Region: North America leads the monoclonal antibodies market owing to its sophisticated healthcare facilities, substantial research and development (R&D) investments, and robust regulatory mandates. The region also benefits from a strong demand for cutting-edge treatments, promoting swift uptake and expansion of monoclonal antibodies.

KEY PLAYERS:

  • The leading companies in monoclonal antibodies market include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GSK plc, Johnson & Johnson, Merck KGaA, Novartis Pharmaceuticals Corporation, Pfizer Inc., Sanofi S.A, and Takeda Pharmaceutical Company Limited.

KEY DRIVERS OF MARKET GROWTH:

  • Increasing Preference for Personalized Medicine: The rise in the popularity of personalized medicine is positively influencing the monoclonal antibodies market by allowing therapies customized to each patient's characteristics. This strategy enables more accurate targeting of disease-related molecules, particularly in situations like cancer and genetic conditions, minimizing side effects and enhancing treatment effectiveness.
  • Investment in Monoclonal Antibody Development: Significant investments in the creation of monoclonal antibodies are speeding up advancements in this area. Venture capital and private equity investments facilitate research, clinical trials, and manufacturing, enabling quicker advancement and market introduction of new treatments.
  • Growing Demand for Biosimilars: With healthcare systems aiming to cut expenses, the need for biosimilars is increasing, leading to greater accessibility of monoclonal antibody treatments. The arrival of new biosimilars in the market expands treatment choices and encourages competition.
  • Supportive Regulatory Environment: Regulatory bodies are enhancing approval procedures for biologics, offering adaptable clinical trial frameworks, and accelerating approvals for sought-after treatments. This regulatory assistance motivates pharmaceutical firms to invest in R&D of monoclonal antibodies.
  • Rising Prevalence of Chronic Diseases: The increasing incidence of chronic illnesses, like cancer and autoimmune conditions, is driving the need for monoclonal antibodies. These conditions necessitate ongoing management, and monoclonal antibodies provide precise, efficient treatments that reduce side effects, rendering them a favored choice for patients and healthcare professionals.
  • Advancements in Biomanufacturing Technologies: Improvements in cell line development, protein expression systems, and bioreactor design are increasing the scalability and effectiveness of monoclonal antibody production. These enhancements lower production expenses, boost yield, and guarantee consistent quality, rendering monoclonal antibody treatments more cost-effective and accessible for various medical conditions.

FUTURE OUTLOOK:

  • Strong Growth Outlook : The monoclonal antibodies market is poised for growth owing to increasing demand for targeted therapies, advancements in biotechnology, and expanding applications across various therapeutic areas. Ongoing research, along with rising healthcare investments, further influences the market potential for sustained expansion and innovation.
  • Market Evolution : The monoclonal antibodies market is undergoing significant evolution, driven by technological advancements and the growing focus on personalized medicine. Ongoing R&D efforts are enhancing the precision and efficacy of treatments, fostering new applications, and expanding the market potential across diverse therapeutic areas.

Monoclonal antibodies (mAbs) are laboratory-produced proteins used to serve as substitute antibodies that can enhance, modify, restore, and mimic the attack of the immune system on unwanted cells. They are utilized for detecting and targeting cancer cells for destruction by enhancing the immune system. They are also employed to block the connection between a cancer cell and proteins that promote cell growth. In addition, they prevent the formation of proteins for enabling immune system cells to work efficiently against cancer cells. Besides this, mAbs transport the radiation treatment directly to cancer cells and minimize the effect of radiation on healthy cells.

MONOCLONAL ANTIBODIES MARKET TRENDS:

Increasing Preference for Personalized Medicine

The shift toward personalized medicine is a vital factor influencing the market, as it enables more precise, effective treatments tailored to individual patient profiles. This method, which customizes medical care for individual patients according to genetic, environmental, and lifestyle factors, is making monoclonal antibodies a favored option for treating certain diseases. These treatments provide precise targeting, focusing solely on the cells or molecules that cause disease, which is vital for conditions, such as cancer or genetic disorders. Tailored medicine enables more efficient therapies with reduced adverse effects, attracting the interest of patients and healthcare professionals alike. As healthcare systems shift towards targeted therapies, the need for monoclonal antibodies increases. This transition is resulting in an increase in research, leading to the development of more monoclonal antibody therapies aimed at different genetic profiles and disease indicators, making sure they cater to the individualized needs of patients.

Investment in Monoclonal Antibody Development

The rise in investment funding for monoclonal antibody development is a significant factor propelling the market growth by accelerating the discovery, production, and commercialization of targeted therapies for various diseases. As venture capital and private equity firms recognize the potential of monoclonal antibodies in treating a wide range of diseases, including inflammatory, autoimmune, and cancer-related conditions, substantial financial backing is flowing into biotech companies. This investment supports research, development, and clinical trials, accelerating the discovery of new monoclonal antibody therapies. The influx of capital enhances innovation, allowing companies to advance their monoclonal antibody pipelines and bring novel treatments to the market. In 2024, Calluna Pharma raised $81 million in a Series A funding round to advance its monoclonal antibody pipeline targeting inflammatory and fibrotic diseases. The company, formed by the merger of Oxitope Pharma and Arxx Therapeutics, was developing four monoclonal antibodies, including CAL101, to address conditions like rheumatoid arthritis and idiopathic pulmonary fibrosis. The funding supported their continued development and clinical trials.

Growing Demand for Biosimilars

Biosimilars, closely resembling existing approved reference monoclonal antibodies, provide a more affordable option while maintaining therapeutic effectiveness. As healthcare systems worldwide face increasing pressure to manage rising treatment costs, biosimilars provide a viable solution by making monoclonal antibody therapies more affordable and accessible. This is especially crucial for managing chronic illnesses like cancer, where the necessity for prolonged therapies can create significant financial strain. The approval and market entry of more biosimilars are expanding treatment options for patients, increasing market competition, and contributing to the overall industry growth. In line with this trend, in 2024, Dr. Reddy's Laboratories launched its first biosimilar, Versavo (bevacizumab), in the UK market. Versavo, a monoclonal antibody biosimilar to Avastin, was used for treating various cancers, including colorectal and breast cancer. This follows its earlier introduction in markets like India, Thailand, and Ukraine.

MONOCLONAL ANTIBODIES MARKET GROWTH DRIVERS:

Supportive Regulatory Environment

The monoclonal antibodies market is significantly supported by an evolving and favorable regulatory environment. Regulatory bodies are simplifying the approval procedure for biologics, including monoclonal antibodies, to hasten access to essential therapies. Due to a rising number of regulatory frameworks and expedited approval routes for in-demand therapies, companies can more swiftly launch new monoclonal antibody treatments. In addition, regulatory agencies are providing increased flexibility in designing clinical trials, making it easier to assess these therapies in various patient groups. This regulatory assistance motivates pharmaceutical firms to invest in the research operations of monoclonal antibodies, as they can expect a more consistent and streamlined approval process for their efforts. With governments acknowledging the significance of innovative treatments, the regulatory landscape remains a crucial element in bolstering the growth of the market. According to a recent monoclonal antibodies market report, this regulatory support is expected to further accelerate industry expansion.

Rising Prevalence of Chronic Diseases

The increasing prevalence of chronic illnesses like cancer, autoimmune disorders, and heart diseases is a major factor propelling the monoclonal antibodies market growth. These conditions necessitate continuous therapy, for which monoclonal antibodies are particularly effective because of their precision and effectiveness in attacking disease-inducing molecules. The aging population is also contributing to this trend, as older adults are more prone to these illnesses. Moreover, from 2024 to 2074, United Nations population forecasts indicate that this figure will double, rising to 20.7%. As the demand for targeted therapies rises, monoclonal antibodies provide a viable solution for both patients and healthcare systems. These treatments can offer more precise and effective outcomes, minimizing side effects compared to traditional therapies. As a result, pharmaceutical companies are investing heavily in the development of monoclonal antibodies for a broad range of medical conditions, further impelling the market growth.

Advancements in Biomanufacturing Technologies

Recent advancements in cell line creation, protein expression technologies, and bioreactor designs are improving the efficiency and scalability of monoclonal antibody production. These advancements in technology aid in lowering production expenses, enhancing yield, and maintaining uniform product quality, thereby making monoclonal antibody treatments more cost-effective and readily available. Moreover, improvements in process optimization and automation allow for greater accuracy in managing manufacturing processes, enhancing overall productivity. As these technologies continue to evolve, they enhance the feasibility of large-scale production, accelerating the availability of monoclonal antibodies for a broader range of therapeutic applications. In 2024, WuXi Biologics launched the WuXia RidGS platform, a high-yield GS-knockout CHO cell line system for non-antibiotic cell line development. It ensured stability for monoclonal antibodies (mAbs) and other therapeutic modalities, with up to 6 g/L expression levels. The platform supported uniform product quality and long-term cell line stability.

MONOCLONAL ANTIBODIES MARKET SEGMENTATION:

Breakup by Production Method:

  • In Vivo
  • In Vitro

Breakup by Source:

  • Murine
  • Chimeric
  • Humanized
  • Human

Breakup by Indication:

  • Cancer
  • Autoimmune Diseases
  • Inflammatory Diseases
  • Infectious Diseases
  • Others

Breakup by End Use:

  • Hospitals
  • Research Institutes
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global monoclonal antibodies market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:

  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Johnson & Johnson
  • Merck KGaA
  • Novartis Pharmaceuticals Corporation
  • Pfizer Inc.
  • Sanofi S.A
  • Takeda Pharmaceutical Company Limited

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Monoclonal Antibodies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Production Method

  • 6.1 In Vivo
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 In Vitro
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Source

  • 7.1 Murine
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Chimeric
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Humanized
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Human
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Autoimmune Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Inflammatory Diseases
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Infectious Diseases
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End Use

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Research Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Amgen Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Bristol-Myers Squibb Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Eli Lilly and Company
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche Ltd.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 GSK plc
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Johnson & Johnson
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck KGaA
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novartis Pharmaceuticals Corporation
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sanofi S.A.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Takeda Pharmaceutical Company Limited
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Monoclonal Antibodies Market: Major Drivers and Challenges
  • Figure 2: Global: Monoclonal Antibodies Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Monoclonal Antibodies Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Monoclonal Antibodies Market: Breakup by Production Method (in %), 2025
  • Figure 5: Global: Monoclonal Antibodies Market: Breakup by Source (in %), 2025
  • Figure 6: Global: Monoclonal Antibodies Market: Breakup by Indication (in %), 2025
  • Figure 7: Global: Monoclonal Antibodies Market: Breakup by End Use (in %), 2025
  • Figure 8: Global: Monoclonal Antibodies Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Monoclonal Antibodies (In Vivo) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Monoclonal Antibodies (In Vivo) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Monoclonal Antibodies (In Vitro) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Monoclonal Antibodies (In Vitro) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Monoclonal Antibodies (Murine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Monoclonal Antibodies (Murine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Monoclonal Antibodies (Chimeric) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Monoclonal Antibodies (Chimeric) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Monoclonal Antibodies (Humanized) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Monoclonal Antibodies (Humanized) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Monoclonal Antibodies (Human) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Monoclonal Antibodies (Human) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Monoclonal Antibodies (Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Monoclonal Antibodies (Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Monoclonal Antibodies (Autoimmune Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Monoclonal Antibodies (Autoimmune Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Monoclonal Antibodies (Inflammatory Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Monoclonal Antibodies (Inflammatory Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Monoclonal Antibodies (Infectious Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Monoclonal Antibodies (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Monoclonal Antibodies (Other Indications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Monoclonal Antibodies (Other Indications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Monoclonal Antibodies (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Monoclonal Antibodies (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Monoclonal Antibodies (Research Institutes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Monoclonal Antibodies (Research Institutes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Monoclonal Antibodies (Other End Uses) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Monoclonal Antibodies (Other End Uses) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: North America: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: North America: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: United States: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: United States: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Canada: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Canada: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Asia-Pacific: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Asia-Pacific: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: China: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: China: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Japan: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Japan: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: India: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: India: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: South Korea: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: South Korea: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Australia: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Australia: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Indonesia: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Indonesia: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Others: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Others: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Europe: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Europe: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Germany: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Germany: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: France: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: France: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: United Kingdom: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: United Kingdom: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Italy: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Italy: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Spain: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Spain: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Russia: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Russia: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Latin America: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Latin America: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Brazil: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Brazil: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Mexico: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Mexico: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Others: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Others: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Middle East and Africa: Monoclonal Antibodies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Middle East and Africa: Monoclonal Antibodies Market: Breakup by Country (in %), 2025
  • Figure 85: Middle East and Africa: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Global: Monoclonal Antibodies Industry: SWOT Analysis
  • Figure 87: Global: Monoclonal Antibodies Industry: Value Chain Analysis
  • Figure 88: Global: Monoclonal Antibodies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Monoclonal Antibodies Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Monoclonal Antibodies Market Forecast: Breakup by Production Method (in Million USD), 2026-2034
  • Table 3: Global: Monoclonal Antibodies Market Forecast: Breakup by Source (in Million USD), 2026-2034
  • Table 4: Global: Monoclonal Antibodies Market Forecast: Breakup by Indication (in Million USD), 2026-2034
  • Table 5: Global: Monoclonal Antibodies Market Forecast: Breakup by End Use (in Million USD), 2026-2034
  • Table 6: Global: Monoclonal Antibodies Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Monoclonal Antibodies Market: Competitive Structure
  • Table 8: Global: Monoclonal Antibodies Market: Key Players